DiaMedica Therapeutics (DMAC) Research & Development (2018 - 2026)

DiaMedica Therapeutics' Research & Development history runs 9 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• On a quarterly basis, Research & Development rose 41.21% year-over-year to $8.0 million in Q1 2026; TTM through Mar 2026 was $26.9 million, a 28.08% increase from a year earlier, with the FY2025 full-year figure at $24.6 million, up 29.16% from the prior year.
• Research & Development grew to $8.0 million in Q1 2026 per DMAC's latest filing, from $6.7 million in the prior quarter.
• Across five years, Research & Development topped out at $8.0 million in Q1 2026 and bottomed at $1.6 million in Q3 2022.
• The 5-year median for Research & Development is $3.7 million (2023), against an average of $4.3 million.
• Across the five-year window, Research & Development declined 29.67% in 2022 and surged 99.51% in 2023, its largest moves.
• Year by year, Research & Development stood at $2.3 million in 2022, then soared by 61.98% to $3.7 million in 2023, then jumped by 75.96% to $6.5 million in 2024, then climbed by 3.54% to $6.7 million in 2025, then climbed by 19.23% to $8.0 million in 2026.
• Per Business Quant, the three latest DMAC Research & Development figures stand at $8.0 million (Q1 2026), $6.7 million (Q4 2025), and $6.4 million (Q3 2025).